Tumors of the hematopoietic and lymphoid tissues

Tessa Therapeutics Announces Collaboration with A*STAR’s Institute of Molecular and Cell Biology to Form Cell Therapy Laboratory

Retrieved on:

Wednesday, June 23, 2021

Tumors of the hematopoietic and lymphoid tissues, Cancer, Treatment of cancer

BEDMINSTER, N.J. and SINGAPORE, June 23, 2021 (GLOBE NEWSWIRE) -- Tessa Therapeutics Ltd. (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and solid tumors, today announced a collaboration agreement with the Agency for Science Technology and Researchs (A*STAR) Institute of Molecular and Cell Biology (IMCB)in Singapore to form a research laboratory.

Key Points:

BEDMINSTER, N.J. and SINGAPORE, June 23, 2021 (GLOBE NEWSWIRE) -- Tessa Therapeutics Ltd. (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and solid tumors, today announced a collaboration agreement with the Agency for Science Technology and Researchs (A*STAR) Institute of Molecular and Cell Biology (IMCB)in Singapore to form a research laboratory.
The agreement marks Tessas second collaboration with IMCB, a research institute within A*STAR, Singapores lead government agency spearheading scientific discovery and innovation in the region.
Tessa Therapeutics is a clinical-stage biotechnology company developing next-generation cell therapies for the treatment of hematological cancers and solid tumors.
Tessa has its global headquarters in Singapore, where the company has built a state of the art, commercial cell therapy manufacturing facility.

ADC Therapeutics Presents Updated ZYNLONTA™ (loncastuximab tesirine-lpyl) Clinical Data at 16th Annual International Conference on Malignant Lymphoma

Retrieved on:

Friday, June 18, 2021

ADC Therapeutics SA (NYSE:ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematological malignancies and solid tumors, announced today that posters on four ZYNLONTA (loncastuximab tesirine-lpyl) clinical trials were presented at the 16th Annual International Conference on Malignant Lymphoma (ICML).

Key Points:

ADC Therapeutics SA (NYSE:ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematological malignancies and solid tumors, announced today that posters on four ZYNLONTA (loncastuximab tesirine-lpyl) clinical trials were presented at the 16th Annual International Conference on Malignant Lymphoma (ICML).
As of the data cut-off date of March 1, 2021, all patients had completed treatment.
ADC Therapeutics CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) is approved by the FDA for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy.
ADC Therapeutics is based in Lausanne (Biople), Switzerland and has operations in London, the San Francisco Bay Area and New Jersey.

COPIKTRA® (duvelisib) Receives European Union Marketing Authorization for the Treatment of Relapsed or Refractory CLL and Refractory FL

Retrieved on:

Wednesday, June 9, 2021

Antineoplastic drugs, Clinical medicine, Medicine, Medical specialties, Oncology, Orphan drugs, Hematology, Duvelisib, Tumors of the hematopoietic and lymphoid tissues, Bone marrow failure, Monoclonal B-cell lymphocytosis, Chronic lymphocytic leukemia

CLL and FL are slow-growing incurable blood cancers that can lead to life-threatening complications such as anemia, serious infections, and bone marrow failure requiring treatment.

Key Points:

CLL and FL are slow-growing incurable blood cancers that can lead to life-threatening complications such as anemia, serious infections, and bone marrow failure requiring treatment.
"This market authorization is an important step in helping patients suffering from relapsed or refractory CLL and FL who currently have limited options and poor outcomes.
"With the market authorization of COPIKTRA in the European Union, Secura Bio will have two meaningful oncology drugs with novel modes of action.
"COPIKTRA provides European physicians and patients with another valuable and beneficial option to combat these debilitating illnesses.

COPIKTRA® (duvelisib) Receives European Union Marketing Authorization for the Treatment of Relapsed or Refractory CLL and Refractory FL

Retrieved on:

Wednesday, June 9, 2021

CLL and FL are slow-growing incurable blood cancers that can lead to life-threatening complications such as anemia, serious infections, and bone marrow failure requiring treatment.

Key Points:

CLL and FL are slow-growing incurable blood cancers that can lead to life-threatening complications such as anemia, serious infections, and bone marrow failure requiring treatment.
"This market authorization is an important step in helping patients suffering from relapsed or refractory CLL and FL who currently have limited options and poor outcomes.
"With the market authorization of COPIKTRA in the European Union, Secura Bio will have two meaningful oncology drugs with novel modes of action.
"COPIKTRA provides European physicians and patients with another valuable and beneficial option to combat these debilitating illnesses.

Gamida Cell Announces Appointment of Senior Vice President, Global Operations and Manufacturing and Provides Commercial Manufacturing Update

Retrieved on:

Monday, June 7, 2021

Oncology, Health, Manufacturing, Other Manufacturing, Pharmaceutical, Biotechnology, Branches of biology, Biology, Life sciences, Cell biology, Tumors of the hematopoietic and lymphoid tissues, Cell therapy, Hematology, Omidubicel, Gamida Cell, OMIDUBICEL, GAMIDA CELL

Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, today announced the appointment of Vladimir Melnikov as senior vice president, global operations and manufacturing.

Key Points:

Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, today announced the appointment of Vladimir Melnikov as senior vice president, global operations and manufacturing.
Mr. Melnikov will have responsibility for the Gamida Cell global operations and manufacturing, which will include the companys Israeli manufacturing site and oversight of the companys contract manufacturing partnership with Lonza.
The scope will focus on both omidubicel and readiness for Gamida Cells natural killer cell platform, including GDA-201.
2 Gamida Cell press release, Gamida Cell Announces Positive Topline Data from Phase 3 Clinical Study of Omidubicel in Patients with High-Risk Hematologic Malignancies, issued May 12, 2020.

LAVA Therapeutics to Present at 2021 Jefferies Virtual Healthcare Conference

Retrieved on:

Tuesday, May 25, 2021

Tumors of the hematopoietic and lymphoid tissues

UTRECHT, The Netherlands and PHILADELPHIA, May 25, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a biotechnology company focused on applying its expertise in bispecific gamma-delta T cell engagers to transform cancer therapy, today announced that Stephen Hurly, chief executive officer, will present at the 2021 Jefferies Virtual Healthcare Conference on Tuesday, June 1, 2021 at 11:30 a.m.

Key Points:

UTRECHT, The Netherlands and PHILADELPHIA, May 25, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a biotechnology company focused on applying its expertise in bispecific gamma-delta T cell engagers to transform cancer therapy, today announced that Stephen Hurly, chief executive officer, will present at the 2021 Jefferies Virtual Healthcare Conference on Tuesday, June 1, 2021 at 11:30 a.m.
The presentation will be webcast and can be accessed from the investor relations section of the company's website at www.lavatherapeutics.com.
LAVA Therapeutics N.V. is a clinical stage biotechnology company developing a portfolio of bispecific gamma-delta T cell engagers (gamma-delta bsTCEs) for the treatment of solid tumors and hematological malignancies based on its proprietary platform.
The Company expects to initiate a Phase 1/2a clinical study to evaluate LAVA-1207 in patients with prostate cancer in the second half of 2021.

Aprea Therapeutics to Participate in the 2021 Oppenheimer Rare & Orphan Disease Summit

Retrieved on:

Friday, May 21, 2021

Tumors of the hematopoietic and lymphoid tissues, Cancer, Protein kinase inhibitors, Bemcentinib, Carboxylic acids, ETV6

The Company\xe2\x80\x99s lead product candidate is eprenetapopt (APR-246), a small molecule in clinical development for hematologic malignancies and solid tumors.

Key Points:

The Company\xe2\x80\x99s lead product candidate is eprenetapopt (APR-246), a small molecule in clinical development for hematologic malignancies and solid tumors.
APR-548, a next generation small molecule reactivator of mutant p53, is being developed for oral administration.
Pre-clinical anti-tumor activity has been observed with eprenetapopt in a wide variety of solid and hematological cancers, including MDS, AML, and ovarian cancer, among others.
We undertake no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.\n'

Transcenta Announced the Results of the Phase I Clinical Study of PD-L1 Antibody MSB2311 with Advanced Solid Tumors and Hematological Malignancies

Retrieved on:

Thursday, May 20, 2021

Tumors of the hematopoietic and lymphoid tissues, Oncology, Clinical medicine, Medicine, Cancer, Cancer treatments, Milatuzumab, Bone metastasis

In the dose escalation Phase, MSB2311 was given at dose levels of 3, 10, and 20mg/kg intravenously every 3 weeks.

Key Points:

In the dose escalation Phase, MSB2311 was given at dose levels of 3, 10, and 20mg/kg intravenously every 3 weeks.
"Patients with metastatic solid tumors or selected lymphoma progressed on or after standard treatments were enrolled in this Phase I study.
This Phase I study showed promising preliminary efficacy and tolerability of MSB2311 in patients with advanced solid tumors and hematological malignancies.
Transcenta is developing a panel of nine antibody molecules for oncology and selected non-oncology indications including bone and kidney disorders.

Aprea Therapeutics to Participate in the 2021 RBC Capital Markets Global Healthcare Conference

Retrieved on:

Tuesday, May 18, 2021

Tumors of the hematopoietic and lymphoid tissues, Cancer, Protein kinase inhibitors, Bemcentinib, Carboxylic acids, ETV6

The Company\xe2\x80\x99s lead product candidate is eprenetapopt (APR-246), a small molecule in clinical development for hematologic malignancies and solid tumors.

Key Points:

The Company\xe2\x80\x99s lead product candidate is eprenetapopt (APR-246), a small molecule in clinical development for hematologic malignancies and solid tumors.
APR-548, a next generation small molecule reactivator of mutant p53, is being developed for oral administration.
Pre-clinical anti-tumor activity has been observed with eprenetapopt in a wide variety of solid and hematological cancers, including MDS, AML, and ovarian cancer, among others.
We undertake no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.\n'

Pregene and Dr. Reddy's Announce License Agreement for Anti-BCMA CAR-T PRG1801 in India

Retrieved on:

Thursday, May 13, 2021

Virotherapy, Biology, Branches of biology, Gene delivery, Molecular genetics, Viral vector, Molecular biology, Lentivirus, Tumors of the hematopoietic and lymphoid tissues

Reddy's acquires the exclusive rights to commercialize PRG1801 in India, and will be responsible for future development including clinical trials, in India.

Key Points:

Reddy's acquires the exclusive rights to commercialize PRG1801 in India, and will be responsible for future development including clinical trials, in India.
Pregene will be the exclusive supplier of the core material - lentiviral vectors for manufacturing PRG1801.
The lentivirus vectors are produced by Pregene using a proprietary serum free suspension production system with gene-therapy-grade quality and a high transduction unit yield.
Pregene's product pipeline includes various cell therapy programs under development for the treatment of hematological malignancies, solid tumors and bone defects.\nDr.